| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 124.40 | 8.7% | 2.0% |
| Total Income | 124.40 | 8.7% | 2.0% |
| Expenditure | 71.95 | 28.0% | 9.1% |
| PBT | 50.24 | 12.1% | 25.3% |
| Net Profit | 37.82 | 16.6% | 10.5% |
| OPM | 42.16% | 8.74pp | 7.07pp |
| NPM | 30.41% | 9.19pp | 2.35pp |
| EPS | 0.17 | 10.5% | 21.4% |
ADMA Biologics Reports Q2 2026 Financial Results, ASCENIV Revenue Up 24% YoY
06 Aug 2026 · 6 Aug, 1:50 am
Summary
ADMA Biologics announced its second quarter 2026 financial results, with total revenue reaching $124.4 million, a 2% increase year-over-year. The company saw significant growth in ASCENIV revenue, which rose 24% to $102.9 million, while BIVIGAM revenue declined but stabilized sequentially. GAAP net income increased by 11% to $37.8 million, and Adjusted EBITDA grew by 22% to $61.8 million. Management expressed confidence in sustained growth throughout the remainder of 2026, supported by accelerating ASCENIV demand and reiterated full-year financial guidance.
Key Highlights
- 1
Second quarter 2026 total revenue was $124.4 million, an increase of 2% year-over-year.
- 2
ASCENIV revenue in the second quarter of 2026 reached $102.9 million, demonstrating 24% growth year-over-year.
- 3
BIVIGAM revenue was $19.4 million in the second quarter of 2026, a 49% decline year-over-year but showing sequential improvement.
- 4
GAAP net income for the second quarter of 2026 was $37.8 million, an increase of 11% year-over-year.
- 5
Adjusted EBITDA for the second quarter of 2026 was $61.8 million, representing 22% year-over-year growth.
- 6
The company reiterated its full-year 2026 financial guidance, expecting total revenue between $530 million and $560 million.
Management Comments
Adam Grossman
Our second quarter results reflect strong execution across the business and demonstrate the power of ASCENIV’s growth trajectory. ASCENIV continued to outperform, supported by increasing physician adoption, broader prescriber engagement, new patient starts and higher patient utilization. Growth in ASCENIV utilization accelerated in the quarter, with June delivering the strongest sequential month-over-month utilization growth since the first half of 2024. BIVIGAM demand continued to stabilize during the quarter, resulting in sequential improvement in utilization and revenue. Together, these trends reinforce our confidence in sustained growth throughout the balance of 2026. During the first half of 2026, ADMA further enhanced its robust real-world health outcomes and healthcare resource utilization data, which we believe further differentiates ASCENIV in later-line, refractory and medically complex primary immunodeficiency patients. We generated data comprising 127 real-world ASCENIV-treated patients, the majority of whom had previously received other immune globulin therapies and switched to ASCENIV. The study’s findings demonstrated that patients experienced statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, oral antibiotic use and corticosteroid use following ASCENIV administration, and the findings have been submitted as an abstract to the November 2026 American College of Allergy, Asthma & Immunology (“ACAAI”) Annual Scientific Meeting. Supported by this expanding real-world evidence base, we believe these datasets will further strengthen ASCENIV’s already robust patient access and commercial payer coverage. We believe ASCENIV remains early in its penetration of this underserved market, supporting our confidence in meeting or exceeding guidance ranges for 2026 and unwavering optimism in the product’s peak revenue potential.
Informational and educational content only. Not investment advice.